Home Free-breathing Functional Pulmonary MRI
Post
Cancel

Free-breathing Functional Pulmonary MRI

Rationale and Objectives

Ventilation heterogeneity is a hallmark feature of asthma. Our objective was to evaluate ventilation heterogeneity in patients with severe asthma, both pre- and post-salbutamol, as well as post-methacholine (MCh) challenge using the lung clearance index, free-breathing pulmonary 1 H magnetic resonance imaging (FDMRI), and inhaled-gas MRI ventilation defect percent (VDP).

Materials and Methods

Sixteen severe asthmatics (49 ± 10 years) provided written informed consent to an ethics board-approved protocol. Spirometry, plethysmography, and multiple breath nitrogen washout to measure the lung clearance index were performed during a single visit within 15 minutes of MRI. Inhaled-gas MRI and FDMRI were performed pre- and post-bronchodilator to generate VDP. For asthmatics with forced expiratory volume in 1 second (FEV 1 ) >70% predicted , MRI was also performed before and after MCh challenge. Wilcoxon signed-rank tests, Spearman correlations, and a repeated-measures analysis of variance were performed.

Results

Hyperpolarized 3 He ( P = .02) and FDMRI ( P = .02) VDP significantly improved post-salbutamol and for four asthmatics who could perform MCh ( n = 4). 3 He and FDMRI VDP significantly increased at the provocative concentration of MCh, resulting in a 20% decrease in FEV 1 (PC 20 ) and decreased post-bronchodilator ( P = .02), with a significant difference between methods ( P = .01). FDMRI VDP was moderately correlated with 3 He VDP (ρ = .61, P = .01), but underestimated VDP relative to 3 He VDP (−6 ± 9%). Whereas 3 He MRI VDP was significantly correlated with the lung clearance index, FDMRI was not (ρ = .49, P = .06).

Conclusions

FDMRI VDP generated in free-breathing asthmatic patients was correlated with static inspiratory breath-hold 3 He MRI VDP but underestimated VDP relative to 3 He MRI VDP. Although less sensitive to salbutamol and MCh, FDMRI VDP may be considered for asthma patient evaluations at centers without inhaled-gas MRI.

Introduction

Asthma is a chronic and often debilitating airways disease, characterized by intermittent worsening of breathlessness, cough, chest tightness, and wheeze, and is typically diagnosed based on spirometry measurements of bronchodilator reversibility or response to methacholine (MCh) challenge using the forced expiratory volume in 1 second (FEV 1 ) . Although current asthma therapies were developed based on FEV 1 improvements , this measurement of airflow limitation is relatively insensitive to small airway obstruction , which is believed to be the main site of inflammation and airway remodeling (or premodeling) in asthma . For many children and adults with asthma, disease control remains elusive, and a recent survey identified that over 90% of Canadian asthmatics reported poorly controlled disease and nearly half did not participate in any exercise of any type due to asthma symptoms . This unacceptable disease morbidity and the large and growing number of asthma patients of all ages have motivated the development of pulmonary imaging approaches to generate new and more sensitive biomarkers of small airway dysfunction. To date, however, it has been complex to use such imaging biomarkers in the development of new therapies in clinical trials or to guide therapy decisions in individual patients.

In asthmatics, thoracic computed tomography (CT) can be used to provide asthma biomarkers of gas-trapping , airway remodeling such as airway wall thickening and lumen narrowing , and dynamic changes in ventilation using xenon-enhanced dual-energy CT . Although ultra low-dose CT methods using iterative adaptive reconstruction methods are now under development , because of radiation dose concerns, the clinical use of CT in asthmatics has been limited, especially in mild disease and in children . Other examples include positron emission tomography and single photon emission computed tomography , both of which have been used in the research setting to evaluate regional ventilation heterogeneity in asthmatics .

Get Radiology Tree app to read full this article<

Get Radiology Tree app to read full this article<

Materials and Methods

Study Logistics and Participants

Get Radiology Tree app to read full this article<

Spirometry, Plethysmography, and Multiple Breath Nitrogen Washout

Get Radiology Tree app to read full this article<

Image Acquisition

Get Radiology Tree app to read full this article<

Get Radiology Tree app to read full this article<

Image Analysis

Get Radiology Tree app to read full this article<

Get Radiology Tree app to read full this article<

Figure 1, FDMRI ventilation map and analysis pipelines. ( a ) Schematic for FDMRI ventilation map generation: (i) coregistered MRI aligned along the time axis; (ii) oscillating signal intensity pattern upon which discrete fast Fourier transforms performed; (iii) magnitude of the frequency of the first ventilation harmonic determined for every voxel; (iv) FDMRI ventilation maps generated. ( b ) Schematic of FDMRI VDP semiautomated segmentation: anatomical 1 H MRI segmented, k-means VDP segmentation, where cluster 1 (C1) = ventilation defects and clusters 2–5 (C2–C5) = hypointense to hyperintense ventilation. FDMRI, Fourier decomposition 1 H magnetic resonance imaging; MRI, magnetic resonance imaging; VDP, ventilation defect percent.

Get Radiology Tree app to read full this article<

Statistics

Get Radiology Tree app to read full this article<

Results

Participant Characteristics

Get Radiology Tree app to read full this article<

TABLE 1

Asthma Demographics, Medication, Control, and Pulmonary Function Tests

Mean (±SD) Asthma All ( n = 16) Severe ( n = 7) Severe Uncontrolled ( n = 9) Age (y) 49 (10) 50 (10) 49 (11) Male, n 6 2 4 BMI, kg ⋅ m −2 28 (4) 28 (5) 28 (4) FEV 1 % pred 66 (24) 64 (19) 68 (28) FVC % pred 84 (14) 85 (12) 83 (16) FEV 1 /FVC % 61 (15) 59 (14) 63 (17) RV % pred 140 (35) 142 (27) 139 (42) TLC % pred 106 (13) 104 (13) 108 (14) RV/TLC % 43 (10) 46 (7) 41 (11) FRC % pred 115 (25) 120 (20) 111 (29) R AW % pred 170 (61) 161 (45) 176 (74) LCI 9.2 (2.6) \* 9.8 (2.6) 8.6 (3.7) † ACQ score 2.0 (1.2) \* 1.2 (0.6) 2.6 (1.2) † AQLQ score 5.0 (1.4) \* 5.8 (0.8) 4.4 (1.5) † mMRC dyspnea score 0.9 (0.7) 0.7 (0.8) 1.0 (0.8) Borg dyspnea 1.4 (1.5) 0.6 (0.7) 2.1 (1.7) ICS, n (%) 16 (100) 7 (100) 9 (100) OCS, n (%) 6 (40) 2 (29) 4 (44) SABA, n (%) 14 (93) 6 (86) 8 (89) LABA, n (%) 16 (100) 7 (100) 9 (100) SAMA, n (%) 3 (20) 1 (14) 2 (22) LAMA, n (%) 4 (27) 1 (14) 3 (33) Anti-IgE, n (%) 3 (20) 1 (14) 2 (22) LTRA, n (%) 7 (47) 3 (43) 4 (44)

% pred , percent of predicted value; ACQ, Asthma Control Questionnaire; anti-IgE, anti-immunoglobulin E; AQLQ, Asthma Quality of Life Questionnaire; BMI, body mass index; FEV 1 , forced expiratory volume in 1 second; FRC, functional residual capacity; FVC, forced vital capacity; ICS, inhaled corticosteroids; LABA, long-acting β2 agonist; LAMA, long-acting anticholinergic; LCI, lung clearance index; LTRA, leukotriene receptor antagonists; mMRC, modified Medical Research Council; OCS, oral corticosteroid; R AW , airways resistance; RV, residual volume; SABA, short-acting β2 agonist; SAMA, short-acting anticholinergic; TLC, total lung capacity.

Get Radiology Tree app to read full this article<

Get Radiology Tree app to read full this article<

Get Radiology Tree app to read full this article<

Ventilation Response to Salbutamol

Get Radiology Tree app to read full this article<

Figure 2, Ventilation MRI for severe and severe uncontrolled asthmatics. ( a ) Hyperpolarized inhaled gas ( cyan ) and FDMRI ( magenta ) for a representative severe asthmatic (female, age = 57 years, baseline FEV 1 = 52% pred , post-salbutamol FEV 1 = 60% pred ) and severe uncontrolled asthmatic (male, age = 56 years, baseline FEV 1 = 37% pred , post-salbutamol FEV 1 = 36% pred ) at baseline and post-salbutamol. Yellow arrows show ventilation defect spatial relationships. ( b ) Box and whisker plot (box = 25th–75th percentile; whiskers = minimum to maximum) for VDP baseline and post-salbutamol for 3 He MRI ( n = 12; baseline VDP = 11.1 ± 10.1%, post-salbutamol VDP = 8.1 ± 7.6%; P = .02) and FDMRI ( n = 12; baseline VDP = 3.9 ± 3.0%, post-salbutamol VDP = 2.8 ± 2.1%; P = .02). FDMRI, Fourier decomposition 1 H magnetic resonance imaging; FEV 1 , forced expiratory volume in 1 second; MRI, magnetic resonance imaging; VDP, ventilation defect percent.

TABLE 2

Subject Listing of Hyperpolarized Inhaled-gas MRI, FDMRI and Multiple Breath Gas Washout Measurements for Each Time Point

Pre-salbutamol PC 20 Post-salbutamol 3 He FDMRI LCI 3 He FDMRI LCI 3 He FDMRI LCI VDP (%) VDP (%) VDP (%) Severe S1 3.6 0.7 7.7 5.2 1.6 – 2.6 1.5 7.3 S2 7.0 7.6 9.5 – – – 3.3 5.5 10.1 S3 2.2 0.6 6.7 – – – 2.4 1.7 6.1 S4 9.1 4.9 13.5 – – – 7.4 2.6 13.2 S5 17.0 1.6 11.7 – – – 17.5 1.2 9.7 S6 10.3 2.3 11.9 – – – 9.6 1.3 10.8 S7 1.0 0.6 7.4 – – – 0.5 0.7 7.7 Mean ± SD 7.2 2.6 9.8 5.2 1.6 – 6.2 2.1 9.3 5.6 2.7 2.6 – – – 5.9 1.6 2.4 Severe uncontrolled S8 27.7 7.9 17.5 – – – 24.2 5.4 15.5 S9 5.2 0.2 8.6 6.0 8.1 – 7.0 1.5 8.2 S10 1.9 0.2 7.1 8.0 5.3 – 1.8 1.5 7.7 S11 2.9 4.9 7.1 – – – 2.4 3.3 6.6 S12 2.1 1.2 6.2 15.8 5.9 – 1.2 0.2 6.5 S13 3.2 1.5 6.4 – – – 3.1 0.7 6.4 S14 32.1 4.7 – – – – 17.2 5.1 – S15 5.7 9.0 7.5 – – – 5.7 6.1 7.4 S16 14.6 1.6 8.7 – – – 3.5 0.3 8.8 Mean ± SD 10.6 3.5 8.6 10.0 6.4 – 7.4 2.7 8.4 11.6 3.3 3.7 5.1 1.5 – 8.0 2.3 3.0

FDMRI, Fourier decomposition 1 H magnetic resonance imaging; LCI, lung clearance index; PC 20 , provocative concentration that decreased the forced expiratory volume in 1 second (FEV 1 ) by 20%; SD, standard deviation; VDP, ventilation defect percent.

Get Radiology Tree app to read full this article<

Ventilation Response to MCh Challenge and Salbutamol Rescue

Get Radiology Tree app to read full this article<

Figure 3, Methacholine challenge. ( a ) Representative severe asthmatic center coronal slice 3 He ( cyan ) MRI and FDMRI ( magenta ) (female, age = 45 years), baseline FEV 1 = 95% pred , PC 20 = 0.123 mg/mL, post-salbutamol FEV 1 = 101% pred at baseline ( 3 He VDP = 3.6%, FDMRI VDP = 0.7%), post-MCh ( 3 He VDP = 5.2%, FDMRI VDP = 1.6%), and post-salbutamol ( 3 He VDP = 2.6%, FDMRI VDP = 1.5%). ( b ) Box and whisker plot (box = 25th–75th percentile; whiskers = minimum to maximum) for 3 He MRI VDP and FDMRI VDP at baseline ( n = 4; 3 He VDP = 3.2 ± 0.8%, FDMRI VDP = 0.6 ± 0.2%), post-MCh ( n = 4; 3 He VDP = 8.8 ± 2.4%, FDMRI VDP = 5.1 ± 1.5%), and post-salbutamol ( n = 4; 3 He VDP = 3.1 ± 1.3%, FDMRI VDP = 1.2 ± 0.7%). FDMRI, Fourier decomposition 1 H magnetic resonance imaging; FEV 1 , forced expiratory volume in 1 second; MCh, methacholine; MRI, magnetic resonance imaging; VDP, ventilation defect percent.

Get Radiology Tree app to read full this article<

Relationships and Agreement

Get Radiology Tree app to read full this article<

Figure 4, Relationships for FDMRI with 3 He MRI. ( a ) FDMRI VDP was significantly correlated with 3 He MRI VDP ( n = 16, ρ = .61, P = .01, y = 0.1×+1.9). ( b ) Bland-Altman analysis of agreement for FDMRI with 3 He MRI VDP ( n = 16, bias = −6.0 ± 8.6%, lower limit = −22.9%, upper limit = 10.8%). Dotted lines indicate the 95% confidence intervals. FDMRI, Fourier decomposition 1 H magnetic resonance imaging; MRI, magnetic resonance imaging; VDP, ventilation defect percent.

TABLE 3

Relationship of Hyperpolarized Inhaled-gas MRI and FDMRI with Pulmonary Function and LCI

Spearman ρ ( P ) 3 He MRI VDP % FDMRI VDP % ( n = 16) ( n = 16) FEV 1 % pred −.78 (.0006) −.45 (.08) FVC % pred −.53 (.03) −.43 (.09) FEV 1 /FVC %−.75 (.001) -.38 (.1) RV % pred .45 (.08).51 (.04) TLC % pred .19 (.5) .35 (.2) RV/TLC % .46 (.07) .28 (.3) FRC % pred .72 (.002).61 (.01) R AW % pred .80 (.0004).57 (.02) LCI.85 (.0001) \* .49 (.06) \* 3 He MRI VDP % –.61 (.01) FDMRI VDP %.61 (.01)

ρ, Spearman correlation coefficients; % pred , percent of predicted value; FDMRI, Fourier decomposition 1 H magnetic resonance imaging; FEV 1 , forced expiratory volume in 1 second; FRC, functional residual capacity; FVC, forced vital capacity; LCI, lung clearance index; MRI, magnetic resonance imaging; R AW , airways resistance; RV, residual volume; TLC, total lung capacity; VDP, ventilation defect percent.

Bold text indicates significant relationships.

Get Radiology Tree app to read full this article<

Get Radiology Tree app to read full this article<

Discussion

Get Radiology Tree app to read full this article<

Get Radiology Tree app to read full this article<

Get Radiology Tree app to read full this article<

Get Radiology Tree app to read full this article<

Get Radiology Tree app to read full this article<

Get Radiology Tree app to read full this article<

Acknowledgments

Get Radiology Tree app to read full this article<

Get Radiology Tree app to read full this article<

Get Radiology Tree app to read full this article<

Get Radiology Tree app to read full this article<

References

  • 1. Global Initiative for Asthma : Global strategy for asthma management and prevention. Available at: www.ginasthma.org Accessed November 11, 2016

  • 2. Crapo R.O., Casaburi R., Coates A.L., et. al.: Guidelines for methacholine and exercise challenge testing-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. Am J Respir Crit Care Med 2000; 161: pp. 309-329.

  • 3. Busse W.W.: Asthma diagnosis and treatment: filling in the information gaps. J Allergy Clin Immunol 2011; 128: pp. 740-750.

  • 4. Gjevre J.A., Hurst T.S., Taylor-Gjevre R.M., et. al.: The American Thoracic Society’s spirometric criteria alone is inadequate in asthma diagnosis. Can Respir J 2006; 13: pp. 433-437.

  • 5. Burgel P.R.: The role of small airways in obstructive airway diseases. Eur Respir Rev 2011; 20: pp. 23-33.

  • 6. Macklem P.T., Mead J.: Resistance of central and peripheral airways measured by a retrograde catheter. J Appl Physiol 1967; 22: pp. 395-401.

  • 7. Tulic M.K., Christodoulopoulos P., Hamid Q.: Small airway inflammation in asthma. Respir Res 2001; 2: pp. 333-339.

  • 8. The Lung Association : Asthma control in Canada TM Survey 2016. Available at: http://mb.lung.ca/file_download/2c91f259-3586-48d9-8496-63530f7f4c9a Accessed November 11, 2016

  • 9. Trivedi A., Hall C., Hoffman E.A., et. al.: Using imaging as a biomarker for asthma. J Allergy Clin Immun 2017; 139: pp. 1-10.

  • 10. Newman K.B., Lynch D.A., Newman L.S., et. al.: Quantitative computed-tomography detects air trapping due to asthma. Chest 1994; 106: pp. 105-109.

  • 11. Aysola R.S., Hoffman E.A., Gierada D., et. al.: Airway remodeling measured by multidetector CT is increased in severe asthma and correlates with pathology. Chest 2008; 134: pp. 1183-1191.

  • 12. Little S.A., Sproule M.W., Cowan M.D., et. al.: High resolution computed tomographic assessment of airway wall thickness in chronic asthma: reproducibility and relationship with lung function and severity. Thorax 2002; 57: pp. 247-253.

  • 13. Kim W.W., Lee C.H., Goo J.M., et. al.: Xenon-enhanced dual-energy CT of patients with asthma: dynamic ventilation changes after methacholine and salbutamol inhalation. AJR Am J Roentgenol 2012; 199: pp. 975-981.

  • 14. Gordic S., Morsbach F., Schmidt B., et. al.: Ultralow-dose chest computed tomography for pulmonary nodule detection: first performance evaluation of single energy scanning with spectral shaping. Invest Radiol 2014; 49: pp. 465-473.

  • 15. Smith-Bindman R., Miglioretti D.L., Johnson E., et. al.: Use of diagnostic imaging studies and associated radiation exposure for patients enrolled in large integrated health care systems, 1996–2010. JAMA 2012; 307: pp. 2400-2409.

  • 16. de Gonzalez A.B., Mahesh M., Kim K.P., et. al.: Projected cancer risks from computed tomographic scans performed in the United States in 2007. Arch Intern Med 2009; 169: pp. 2071-2077.

  • 17. Smith-Bindman R., Lipson J., Marcus R., et. al.: Radiation dose associated with common computed tomography examinations and the associated lifetime attributable risk of cancer. Arch Intern Med 2009; 169: pp. 2078-2086.

  • 18. Venegas J.G., Winkler T., Musch G., et. al.: Self-organized patchiness in asthma as a prelude to catastrophic shifts. Nature 2005; 434: pp. 777-782.

  • 19. King G.G., Eberl S., Salome C.M., et. al.: Airway closure measured by a Technegas bolus and SPECT. Am J Respir Crit Care Med 1997; 155: pp. 682-688.

  • 20. King G.G., Eberl S., Salome C.M., et. al.: Differences in airway closure between normal and asthmatic subjects measured with single-photon emission computed tomography and Technegas. Am J Respir Crit Care Med 1998; 158: pp. 1900-1906.

  • 21. de Lange E.E., Altes T.A., Patrie J.T., et. al.: Changes in regional airflow obstruction over time in the lungs of patients with asthma: evaluation with 3He MR imaging. Radiology 2009; 250: pp. 567-575.

  • 22. Svenningsen S., Kirby M., Starr D., et. al.: What are ventilation defects in asthma?. Thorax 2014; 69: pp. 63-71.

  • 23. Samee S., Altes T., Powers P., et. al.: Imaging the lungs in asthmatic patients by using hyperpolarized helium-3 magnetic resonance: assessment of response to methacholine and exercise challenge. J Allergy Clin Immunol 2003; 111: pp. 1205-1211.

  • 24. Svenningsen S., Kirby M., Starr D., et. al.: Hyperpolarized (3) He and (129) Xe MRI: differences in asthma before bronchodilation. J Magn Reson Imaging 2013; 38: pp. 1521-1530.

  • 25. de Lange E.E., Altes T.A., Patrie J.T., et. al.: Evaluation of asthma with hyperpolarized helium-3 MRI: correlation with clinical severity and spirometry. Chest 2006; 130: pp. 1055-1062.

  • 26. Fain S.B., Gonzalez-Fernandez G., Peterson E.T., et. al.: Evaluation of structure-function relationships in asthma using multidetector CT and hyperpolarized He-3 MRI. Acad Radiol 2008; 15: pp. 753-762.

  • 27. Svenningsen S., Nair P., Guo F., et. al.: Is ventilation heterogeneity related to asthma control?. Eur Respir J 2016; 48: pp. 370-379.

  • 28. Ohno Y., Koyama H., Matsumoto K., et. al.: Oxygen-enhanced MRI vs. quantitatively assessed thin-section CT: pulmonary functional loss assessment and clinical stage classification of asthmatics. Eur J Radiol 2011; 77: pp. 85-91.

  • 29. Zhang W.J., Niven R.M., Young S.S., et. al.: Dynamic oxygen-enhanced magnetic resonance imaging of the lung in asthma – initial experience. Eur J Radiol 2015; 84: pp. 318-326.

  • 30. Zapke M., Topf H.G., Zenker M., et. al.: Magnetic resonance lung function–a breakthrough for lung imaging and functional assessment? A phantom study and clinical trial. Respir Res 2006; 7: pp. 106.

  • 31. Pennati F., Quirk J.D., Yablonskiy D.A., et. al.: Assessment of regional lung function with multivolume (1)H MR imaging in health and obstructive lung disease: comparison with (3)He MR imaging. Radiology 2014; 273: pp. 580-590.

  • 32. Bauman G., Puderbach M., Deimling M., et. al.: Non-contrast-enhanced perfusion and ventilation assessment of the human lung by means of Fourier decomposition in proton MRI. Magn Reson Med 2009; 62: pp. 656-664.

  • 33. Bauman G., Lützen U., Ullrich M., et. al.: Pulmonary functional imaging: qualitative comparison of Fourier decomposition MR imaging with SPECT/CT in porcine lung. Radiology 2011; 260: pp. 551-559.

  • 34. Bauman G., Scholz A., Rivoire J., et. al.: Lung ventilation-and perfusion-weighted Fourier decomposition magnetic resonance imaging: In vivo validation with hyperpolarized 3He and dynamic contrast-enhanced MRI. Magn Reson Med 2013; 69: pp. 229-237.

  • 35. Capaldi D.P., Sheikh K., Guo F., et. al.: Free-breathing pulmonary (1)H and hyperpolarized (3)He MRI: comparison in COPD and bronchiectasis. Acad Radiol 2015; 22: pp. 320-329.

  • 36. Miller M.R., Hankinson J., Brusasco V., et. al.: Standardisation of spirometry. Eur Respir J 2005; 26: pp. 319-338.

  • 37. Parraga G., Ouriadov A., Evans A., et. al.: Hyperpolarized 3He ventilation defects and apparent diffusion coefficients in chronic obstructive pulmonary disease: preliminary results at 3.0 Tesla. Invest Radiol 2007; 42: pp. 384-391.

  • 38. Kirby M., Heydarian M., Svenningsen S., et. al.: Hyperpolarized 3He magnetic resonance functional imaging semiautomated segmentation. Acad Radiol 2012; 19: pp. 141-152.

  • 39. Heinrich M.P., Jenkinson M., Bhushan M., et. al.: MIND: modality independent neighbourhood descriptor for multi-modal deformable registration. Med Image Anal 2012; 16: pp. 1423-1435.

  • 40. Altman D.G.: Practical statistics for medical research.1990.CRC PressBoca Raton, FL

  • 41. Hamedani H., Clapp J.T., Kadlecek S.J., et. al.: Regional fractional ventilation by using multibreath wash-in (3)He MR imaging. Radiology 2016; 279: pp. 917-924.

  • 42. Costella S., Kirby M., Maksym G.N., et. al.: Regional pulmonary response to a methacholine challenge using hyperpolarized (3)He magnetic resonance imaging. Respirology 2012; 17: pp. 1237-1246.

  • 43. Yu J., Xue Y., Song H.K.: Comparison of lung T2* during free-breathing at 1.5 T and 3.0 T with ultrashort echo time imaging. Magn Reson Med 2011; 66: pp. 248-254.

  • 44. Bauman G., Pusterla O., Bieri O.: Ultra-fast steady-state free precession pulse sequence for Fourier decomposition pulmonary MRI. Magn Reson Med 2016; 75: pp. 1647-1653.

  • 45. Sheikh K., Guo F., Capaldi D.P., et. al.: Ultrashort echo time MRI biomarkers of asthma. J Magn Reson Imaging 2017; 45: pp. 1204-1215.

This post is licensed under CC BY 4.0 by the author.